<DOC>
	<DOCNO>NCT00090701</DOCNO>
	<brief_summary>The primary objective study determine safety activity novel anticancer agent patient metastatic non-small cell lung cancer fail 2 3 prior systemic treatment .</brief_summary>
	<brief_title>A Phase 2 , Open-Label , Multicenter Study GARFT Inhibitor Patients With Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>presence measurable , metastatic nonsmall cell lung cancer ( histologically cytologically confirmed time original diagnosis ) treatment failure ( recurrence , disease progression , intolerable toxicity ) 2 3 prior systemic treatment . ( Note : 3 prior systemic regimen nonsmall cell lung cancer include adjuvant chemotherapy ) capable understanding nature trial willing give write informed consent Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 hemoglobin level &gt; =9 g/dL , absolute granulocyte count &gt; =1.5 &amp; # 215 ; 109/L , platelet count &gt; =100 &amp; # 215 ; 109/L adequate renal function , document serum creatinine level &lt; =1.5 time institutional upper limit normal ( ULN ) measure calculated creatinine clearance &gt; =60 mL/min adequate liver function , demonstrate total bilirubin level &lt; =1.5 time ULN ; level serum glutamate oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; =2 time ULN . If patient liver involvement AST ALT &lt; =5 time ULN men partner childbearing potential woman childbearing potential , willingness use adequate contraception practice abstinence course study least 18 year age life expectancy estimate great 12 week history blood transfusion within last 14 day need concurrent administration allopurinol history radiotherapy chemotherapy within 4 week ( nitrosourea mitomycin C within 6 week ) anticipate first day dose ( patient must fully recover acute effect prior chemotherapy radiotherapy ) psychological sociological condition , addictive disorder , family problem might preclude compliance protocol unstable severe intercurrent medical condition opinion investigator might interfere achievement study objective receipt investigational agent within 28 day anticipate first day dose ( patient must recover acute effect previously administer investigational agent ) pregnant breastfeed previous treatment GARFT inhibitor history radiation therapy 40 % marrow space history malignancy ( nonsmall cell lung cancer ) except treat curative intent skin cancer ( melanoma ) situ breast cervical cancer treat curative intent cancer evidence disease 5 year active brain metastasis ( require treatment progressing )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>